Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers lifted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 30.3% during the second quarter, HoldingsChannel reports. The firm owned 107,338 shares of the company’s stock after purchasing an additional 24,940 shares during the quarter. Rhumbline Advisers’ holdings in Akero Therapeutics were worth $2,518,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Quarry LP lifted its position in shares of Akero Therapeutics by 40.0% during the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after purchasing an additional 500 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after purchasing an additional 1,030 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Akero Therapeutics by 15.6% during the first quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after purchasing an additional 1,858 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Akero Therapeutics by 24.4% during the first quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock worth $379,000 after purchasing an additional 2,945 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Tuesday. Finally, Wolfe Research assumed coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Insider Transactions at Akero Therapeutics

In other news, insider Catriona Yale sold 3,871 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $27.56, for a total transaction of $106,684.76. Following the completion of the transaction, the insider now owns 75,294 shares in the company, valued at $2,075,102.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $23.40, for a total value of $117,000.00. Following the completion of the sale, the chief operating officer now owns 246,854 shares of the company’s stock, valued at $5,776,383.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Catriona Yale sold 3,871 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76. Following the completion of the sale, the insider now directly owns 75,294 shares of the company’s stock, valued at approximately $2,075,102.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 283,042 shares of company stock worth $7,679,955. Insiders own 7.94% of the company’s stock.

Akero Therapeutics Stock Up 1.2 %

AKRO stock opened at $26.96 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.89 and a quick ratio of 24.89. Akero Therapeutics, Inc. has a 1-year low of $11.25 and a 1-year high of $53.00. The firm has a fifty day moving average price of $26.22 and a two-hundred day moving average price of $23.95. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -8.43 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. Research analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.